Toronto Dominion Bank Sells 2,864 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Toronto Dominion Bank reduced its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 43.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,706 shares of the medical research company’s stock after selling 2,864 shares during the period. Toronto Dominion Bank’s holdings in Bio-Rad Laboratories were worth $1,240,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Capital Advisors Ltd. LLC increased its stake in shares of Bio-Rad Laboratories by 193.8% in the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after purchasing an additional 62 shares in the last quarter. UMB Bank n.a. boosted its holdings in Bio-Rad Laboratories by 140.6% in the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after buying an additional 45 shares during the period. Gladius Capital Management LP purchased a new position in Bio-Rad Laboratories in the 3rd quarter valued at approximately $32,000. Headlands Technologies LLC bought a new stake in Bio-Rad Laboratories during the 2nd quarter valued at $51,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of Bio-Rad Laboratories during the third quarter worth $55,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO opened at $343.19 on Tuesday. The stock’s 50-day simple moving average is $341.40 and its two-hundred day simple moving average is $321.72. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The firm has a market capitalization of $9.61 billion, a P/E ratio of -12.56 and a beta of 0.90. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. During the same period in the prior year, the business earned $2.33 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was up 2.8% compared to the same quarter last year. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BIO shares. Citigroup lifted their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Royal Bank of Canada lifted their target price on Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an “outperform” rating in a report on Monday, December 9th. StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price objective for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Bio-Rad Laboratories has an average rating of “Moderate Buy” and an average price target of $394.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.